US FDA approves Pfizer’s oral antiviral Paxlovid to treat Covid-19 in adults
Paxlovid is an oral SARS-CoV-2 main protease (Mpro) inhibitor therapy, containing 300mg nirmatrelvir and 100mg ritonavir at a standard dose, prescribed early after infection to help prevent potential severe Covid-19 in adult patients